Type of test Nuclear scan
Normal findings
No increased uptake outside the prostate gland
Test explanation and related physiology
By using a radionuclide that is able to attach to prostate cancer cells only, metastatic prostate cancer outside the prostate gland can be easily identified. Disease outside the prostate (e.g., retroperitoneum, liver, lung, or bone) indicates metastatic prostate cancer.
This scan is helpful in staging newly diagnosed prostate cancer patients who are at high risk for metastatic disease to the lymph nodes or other organs. This test can also be used to identify recurrent or metastatic disease after curative therapy. This test can document completeness of anti–prostate cancer therapy.
Contraindications
• Patients who are unable to be immobile for 1 hour
Interfering factors
• Prior bone scans confound image interpretation.
• Areas of inflammation (e.g., degenerative joint disease, inflammatory bowel disease, or recent trauma) can confound interpretation.
Procedure and patient care
Before
* Explain the procedure to the patient.
* Explain that no fasting is required before the test.
* Instruct the patient to use a mild laxative the evening before imaging. A cleansing enema may be administered 1 hour before imaging. Early in the scanning, radionuclide accumulates in the bowel.
* Tell the patient to void before each image.
During
• After proper identification, the patient is injected with the radiolabeled monoclonal antibody.
• Initial images are obtained 30 minutes after injection. Images are repeated over as many as 5 days.
• Little or no discomfort is associated with this procedure.
• The procedure takes approximately 1 hour each day over a period of 1 to 5 days.
• This procedure is performed in the nuclear medicine department.
After
* Inform the patient that no precautions need to be taken by others against radiation exposure because only tracer doses of radioisotopes are used.
• Encourage the patient to increase oral fluid intake on testing days.
Abnormal findings
- Primary or recurrent prostate cancer